Dermatomyositis and lupus may share symptoms in some cases. Here's what you need to know about these autoimmune conditions.

Dazukibart, a type I interferon inhibitor, reduced dermatomyositis disease severity while maintaining a well-tolerated safety ...

Dermatomyositis is a rare inflammatory disease characterized by muscle weakness and skin rash. The exact cause is unknown, ...

Exposures to silica dust, solvents or heavy metals increase the likelihood of developing various forms of myositis, ...

The following is a summary of “Validity of diagnosis codes to identify a dermatomyositis cohort from electronic health records,” published in the January 2025 issue of Dermatology by Silberzweig et al ...

Achievement of cancer remission was associated with dermatomyositis complete clinical response among patients with cancer-associated DM.

Q3 2024 Management View CEO Matt Gline highlighted 2025 as a year of major milestones, focusing on validating the anti-FcRn franchise with upcoming MG and CIDP data and a central registrational ...

Reports Q3 revenue $9.02M, consensus $4.75M. “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in ...

Despite the recent rise in herbal supplement use, research suggests certain supplements may pose risks for patients with autoimmune diseases.

Treatment with dazukibart, a monoclonal antibody targeting interferon beta, yielded a rapid reduction in dermatomyositis disease activity in adults with skin-predominant and muscle-predominant ...